PropertyValue
?:abstract
  • Amperialâ„¢ is a novel assay platform that uses immobilized antigen in a conductive polymer gel followed by an electrochemical detection. A highly specific and sensitive assay was developed to quantify levels of IgG antibodies to SARS-CoV-2 in saliva. After establishing linearity and limit of detection we established a reference range of 5 standard deviations above the mean. There were no false positives in 667 consecutive saliva samples obtained prior to 2019. Saliva was obtained from 34 patients who had recovered from documented COVID-19 or had documented positive serologies. All of the patients with symptoms severe enough to seek medical attention had positive antibody tests and 88% overall had positive results. We obtained blinded paired saliva and plasma samples from 14 individuals. The plasma was analyzed using an EUA-FDA cleared ELISA kit and the saliva was analyzed by our Amperialâ„¢ assay. All 5 samples with negative plasma titers were negative in saliva testing. Eight of the 9 positive plasma samples were positive in saliva and 1 had borderline results. A CLIA validation was performed as a laboratory developed test in a high complexity laboratory. A quantitative non-invasive saliva based SARSCoV-2 antibody test was developed and validated with sufficient specificity to be useful for population-based monitoring and monitoring of individuals following vaccination.
is ?:annotates of
?:creator
?:doi
  • 10.1101/2020.11.12.20230656
?:doi
?:journal
  • medRxiv
?:license
  • cc-by
?:pmc_json_files
  • document_parses/pmc_json/PMC7685352.xml.json
?:pmcid
?:pmid
?:pmid
  • 33236034.0
?:publication_isRelatedTo_Disease
?:source
  • MedRxiv; Medline; PMC; WHO
?:title
  • Development and validation of a highly sensitive and specific electrochemical assay to quantify anti-SARS-CoV-2 IgG antibodies to facilitate pandemic surveillance and monitoring of vaccine response.
?:type
?:year
  • 2020-11-16

Metadata

Anon_0  
expand all